Clinical Trial Update: Recombinant vWF Concentrate and ECMO [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a recombinant von Willebrand factor concentrate in patients undergoing ECMO for a bleeding disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Recombinant von Willebrand Factor concentrate (rVWF) (recombinant von Willebrand factor concentrate)

Snippet

Sponsor: University of Virginia | Conditions: Bleeding Disorder | Phase 1 | Status: RECRUITING